Skip to main content
Top
Published in: BMC Nephrology 1/2014

Open Access 01-12-2014 | Case report

A case of granulomatosis with polyangiitis complicated by cyclophosphamide toxicity and opportunistic infections: choosing between Scylla and Charybdis

Authors: Elena Ernst, Matthias Girndt, Rainer U Pliquett

Published in: BMC Nephrology | Issue 1/2014

Login to get access

Abstract

Background

We report a case of progressive Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) with life-threatening complications of both the underlying disease and induction immunosuppressive therapy. Here, for the first time, cyclophosphamide toxicity and severe opportunistic infections including pneumocystis jirovecii- pneumonia were found in one case in a close temporal relationship.

Case presentation

A 34-year-old male patient of Caucasian ethnicity presented with acute renal failure necessitating hemodialysis treatment due to Granulomatosis with Polyangiitis (Wegener’s Granulomatosis). Kidney disease progressed to end-stage renal disease shortly after first diagnosis. After the 2nd bolus of cyclophosphamide shortly, induction immunosuppression (glucocorticoid/cyclophosphamide) was interrupted for repeat infections and resumed 5 years later. By that time, the lungs developed large pulmonary cavernae most likely due to smoldering granuloma indicative for the failed goal of disease remission. Therefore, induction immunosuppression was resumed. Following two monthly boli of cyclophosphamide, the patient developed pericardial effusion and, consecutively, atrioventricular blockade most likely due to cyclophosphamide. After recovery, the patient was discharged without cotrimoxacole. 10 weeks after the last cyclophosphamide bolus and 6 weeks after cessation of cotrimoxacole, the patient was readmitted to the intensive-care unit with Pneumocystis jirovecii pneumonia, and died 6 months later or 74 months after first diagnosis of Granulomatosis with Polyangiitis.

Conclusions

This case illustrates both the need for adequate immunosuppressive therapy to reach disease remission and the limitations thereof in terms of complications including cardiotoxicity of cyclophosphamide and Pneumocystis jirovecii pneumonia. In line with current recommendations, the present case strongly encourages pneumocystis jirovecii- pneumonia chemoprophylaxis for at least 6 months following induction therapy in Granulomatosis with Polyangiitis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ahmed M, Niffenegger JH, Jakobiec FA, Ben-Arie-Weintrob Y, Gion N, Androudi S, et al: Diagnosis of limited ophthalmic Wegener granulomatosis: distinctive pathologic features with ANCA test confirmation. Int Ophthalmol. 2008, 28: 35-46. 10.1007/s10792-007-9109-y.CrossRefPubMed Ahmed M, Niffenegger JH, Jakobiec FA, Ben-Arie-Weintrob Y, Gion N, Androudi S, et al: Diagnosis of limited ophthalmic Wegener granulomatosis: distinctive pathologic features with ANCA test confirmation. Int Ophthalmol. 2008, 28: 35-46. 10.1007/s10792-007-9109-y.CrossRefPubMed
2.
go back to reference Bacon PA: The spectrum of Wegener’s granulomatosis and disease relapse. N Engl J Med. 2005, 352: 330-332. 10.1056/NEJMp048338.CrossRefPubMed Bacon PA: The spectrum of Wegener’s granulomatosis and disease relapse. N Engl J Med. 2005, 352: 330-332. 10.1056/NEJMp048338.CrossRefPubMed
3.
go back to reference Ghaussy NO, Du Clos TW, Ashley PA: Limited Wegener’s granulomatosis presenting with complete heart block. Scand J Rheumatol. 2004, 33: 115-118. 10.1080/03009740310004063.CrossRefPubMed Ghaussy NO, Du Clos TW, Ashley PA: Limited Wegener’s granulomatosis presenting with complete heart block. Scand J Rheumatol. 2004, 33: 115-118. 10.1080/03009740310004063.CrossRefPubMed
4.
go back to reference Qian Q, Cornell L, Chandan V, Hartman R, Caples S: Hemorrhagic colitis as a presenting feature of Wegener granulomatosis. J Gastrointestin Liver Dis. 2010, 19: 445-447.PubMed Qian Q, Cornell L, Chandan V, Hartman R, Caples S: Hemorrhagic colitis as a presenting feature of Wegener granulomatosis. J Gastrointestin Liver Dis. 2010, 19: 445-447.PubMed
5.
go back to reference Sarlon G, Durant C, Grandgeorge Y, Bernit E, Veit V, Hamidou M, et al: Cardiac involvement in Wegener’s granulomatosis: report of four cases and review of the literature. Rev Med Interne. 2010, 31: 135-139. 10.1016/j.revmed.2009.06.007.CrossRefPubMed Sarlon G, Durant C, Grandgeorge Y, Bernit E, Veit V, Hamidou M, et al: Cardiac involvement in Wegener’s granulomatosis: report of four cases and review of the literature. Rev Med Interne. 2010, 31: 135-139. 10.1016/j.revmed.2009.06.007.CrossRefPubMed
6.
go back to reference Bacon PA: The spectrum of Wegener’s granulomatosis and disease relapse. N Engl J Med. 2005, 352: 330-332. 10.1056/NEJMp048338.CrossRefPubMed Bacon PA: The spectrum of Wegener’s granulomatosis and disease relapse. N Engl J Med. 2005, 352: 330-332. 10.1056/NEJMp048338.CrossRefPubMed
7.
go back to reference Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de GK, Gross W, et al: EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009, 68: 310-317. 10.1136/ard.2008.088096.CrossRefPubMed Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de GK, Gross W, et al: EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009, 68: 310-317. 10.1136/ard.2008.088096.CrossRefPubMed
8.
go back to reference Green H, Paul M, Vidal L, Leibovici L: Prophylaxis of pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007, 82: 1052-1059. 10.4065/82.9.1052.CrossRefPubMed Green H, Paul M, Vidal L, Leibovici L: Prophylaxis of pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007, 82: 1052-1059. 10.4065/82.9.1052.CrossRefPubMed
9.
go back to reference Stegeman CA, Tervaert JW, De Jong PE, Kallenberg CG: Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996, 335: 16-20. 10.1056/NEJM199607043350103.CrossRefPubMed Stegeman CA, Tervaert JW, De Jong PE, Kallenberg CG: Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996, 335: 16-20. 10.1056/NEJM199607043350103.CrossRefPubMed
10.
go back to reference Zycinska K, Wardyn KA, Zielonka TM, Krupa R, Lukas W: Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement. Eur J Med Res. 2009, 14 (Suppl 4): 265-267. 10.1186/2047-783X-14-S4-265.CrossRefPubMedPubMedCentral Zycinska K, Wardyn KA, Zielonka TM, Krupa R, Lukas W: Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement. Eur J Med Res. 2009, 14 (Suppl 4): 265-267. 10.1186/2047-783X-14-S4-265.CrossRefPubMedPubMedCentral
11.
go back to reference Cettomai D, Gelber AC, Christopher-stine L: A survey of RheumatologistsΓÇÖ practice for prescribing pneumocystis prophylaxis. J Rheumatol. 2010, 37: 792-799. 10.3899/jrheum.090843.CrossRefPubMed Cettomai D, Gelber AC, Christopher-stine L: A survey of RheumatologistsΓÇÖ practice for prescribing pneumocystis prophylaxis. J Rheumatol. 2010, 37: 792-799. 10.3899/jrheum.090843.CrossRefPubMed
12.
go back to reference Grewal P, Brassard A: Fact or fiction: does the non-HIV/AIDS immunosuppressed patient need Pneumocystis jiroveci pneumonia prophylaxis? An updated literature review. J Cutan Med Surg. 2009, 13: 308-312.CrossRefPubMed Grewal P, Brassard A: Fact or fiction: does the non-HIV/AIDS immunosuppressed patient need Pneumocystis jiroveci pneumonia prophylaxis? An updated literature review. J Cutan Med Surg. 2009, 13: 308-312.CrossRefPubMed
13.
go back to reference Mehta R, Kellum J, Shah S, Molitoris B, Ronco C, Warnock D, et al: Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007, 11: R31-10.1186/cc5713.CrossRefPubMedPubMedCentral Mehta R, Kellum J, Shah S, Molitoris B, Ronco C, Warnock D, et al: Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007, 11: R31-10.1186/cc5713.CrossRefPubMedPubMedCentral
14.
go back to reference Jayne DRW, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al: Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007, 18: 2180-2188. 10.1681/ASN.2007010090.CrossRefPubMed Jayne DRW, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al: Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007, 18: 2180-2188. 10.1681/ASN.2007010090.CrossRefPubMed
15.
go back to reference Stamp LK, Hurst M: Is there a role for consensus guidelines for P. jiroveci pneumonia prophylaxis in immunosuppressed patients with rheumatic diseases?. J Rheumatol. 2010, 37: 686-688. 10.3899/jrheum.091426.CrossRefPubMed Stamp LK, Hurst M: Is there a role for consensus guidelines for P. jiroveci pneumonia prophylaxis in immunosuppressed patients with rheumatic diseases?. J Rheumatol. 2010, 37: 686-688. 10.3899/jrheum.091426.CrossRefPubMed
16.
go back to reference Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de GK, Gross W, et al: EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009, 68: 310-317. 10.1136/ard.2008.088096.CrossRefPubMed Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de GK, Gross W, et al: EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009, 68: 310-317. 10.1136/ard.2008.088096.CrossRefPubMed
17.
go back to reference Issue S: KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009, 9: S1-S155. Issue S: KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009, 9: S1-S155.
18.
go back to reference EBPG Expert Group on Renal Transplantation: European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. Nephrol Dial Transplant. 2002, 17 (Suppl 4): 1-67. EBPG Expert Group on Renal Transplantation: European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. Nephrol Dial Transplant. 2002, 17 (Suppl 4): 1-67.
19.
go back to reference Godeau B, Mainardi JL, Roudot-Thoraval F, Hachulla E, Guillevin L, Du Huong LT, et al: Factors associated with pneumocystis carinii pneumonia in Wegener’s granulomatosis. Ann Rheum Dis. 1995, 54: 991-994. 10.1136/ard.54.12.991.CrossRefPubMedPubMedCentral Godeau B, Mainardi JL, Roudot-Thoraval F, Hachulla E, Guillevin L, Du Huong LT, et al: Factors associated with pneumocystis carinii pneumonia in Wegener’s granulomatosis. Ann Rheum Dis. 1995, 54: 991-994. 10.1136/ard.54.12.991.CrossRefPubMedPubMedCentral
20.
go back to reference Girndt M, Sester U, Sester M, Kaul H, K+Âhler H: Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant. 1999, 14: 2807-2810. 10.1093/ndt/14.12.2807.CrossRefPubMed Girndt M, Sester U, Sester M, Kaul H, K+Âhler H: Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant. 1999, 14: 2807-2810. 10.1093/ndt/14.12.2807.CrossRefPubMed
21.
go back to reference Haubitz M, Koch KM, Brunkhorst R: Survival and vasculitis activity in patients with end-stage renal disease due to Wegener’s granulomatosis. Nephrol Dial Transplant. 1998, 13: 1713-1718. 10.1093/ndt/13.7.1713.CrossRefPubMed Haubitz M, Koch KM, Brunkhorst R: Survival and vasculitis activity in patients with end-stage renal disease due to Wegener’s granulomatosis. Nephrol Dial Transplant. 1998, 13: 1713-1718. 10.1093/ndt/13.7.1713.CrossRefPubMed
22.
go back to reference Goldberg MA, Antin JH, Guinan EC, Rappeport JM: Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. 1986, 68: 1114-1118.PubMed Goldberg MA, Antin JH, Guinan EC, Rappeport JM: Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. 1986, 68: 1114-1118.PubMed
23.
go back to reference Katayama M, Imai Y, Hashimoto H, Kurata M, Nagai K, Tamita K, et al: Fulminant fatal cardiotoxicity following cyclophosphamide therapy. J Cardiol. 2009, 54: 330-334. 10.1016/j.jjcc.2009.01.006.CrossRefPubMed Katayama M, Imai Y, Hashimoto H, Kurata M, Nagai K, Tamita K, et al: Fulminant fatal cardiotoxicity following cyclophosphamide therapy. J Cardiol. 2009, 54: 330-334. 10.1016/j.jjcc.2009.01.006.CrossRefPubMed
24.
go back to reference Tiersten A, Wo J, Jacobson C, Weitzman A, Horwich T, Hesdorffer C, et al: Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer. Breast. 2004, 13: 341-346. 10.1016/j.breast.2004.02.007.CrossRefPubMed Tiersten A, Wo J, Jacobson C, Weitzman A, Horwich T, Hesdorffer C, et al: Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer. Breast. 2004, 13: 341-346. 10.1016/j.breast.2004.02.007.CrossRefPubMed
25.
go back to reference Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D: Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int. 2002, 61: 1495-1501. 10.1046/j.1523-1755.2002.00279.x.CrossRefPubMed Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D: Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int. 2002, 61: 1495-1501. 10.1046/j.1523-1755.2002.00279.x.CrossRefPubMed
26.
go back to reference Stegeman CA, Tervaert JW, PE DJ, Kallenberg CG: Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996, 335: 16-20. 10.1056/NEJM199607043350103.CrossRefPubMed Stegeman CA, Tervaert JW, PE DJ, Kallenberg CG: Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996, 335: 16-20. 10.1056/NEJM199607043350103.CrossRefPubMed
27.
go back to reference Zycinska K, Wardyn KA, Zielonka TM, Krupa R, Lukas W: Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement. Eur J Med Res. 2009, 14 (Suppl 4): 265-267. 10.1186/2047-783X-14-S4-265.CrossRefPubMedPubMedCentral Zycinska K, Wardyn KA, Zielonka TM, Krupa R, Lukas W: Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement. Eur J Med Res. 2009, 14 (Suppl 4): 265-267. 10.1186/2047-783X-14-S4-265.CrossRefPubMedPubMedCentral
28.
go back to reference Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, Woywodt A, et al: Diagnostic role of endothelial microparticles in vasculitis. Rheumatology. 2008, 47: 1820-1825. 10.1093/rheumatology/ken373.CrossRefPubMed Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, Woywodt A, et al: Diagnostic role of endothelial microparticles in vasculitis. Rheumatology. 2008, 47: 1820-1825. 10.1093/rheumatology/ken373.CrossRefPubMed
Metadata
Title
A case of granulomatosis with polyangiitis complicated by cyclophosphamide toxicity and opportunistic infections: choosing between Scylla and Charybdis
Authors
Elena Ernst
Matthias Girndt
Rainer U Pliquett
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2014
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-15-28

Other articles of this Issue 1/2014

BMC Nephrology 1/2014 Go to the issue